Trial Profile
Efficacy of crizotinib in alectinib-refractory patients with NSCLC harboring EML4-ALK; phaseII trial (OLCSG1405)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2022
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Jan 2021 Status changed from recruiting to completed, according to results presented at the 2020 World Conference on Lung Cancer.
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer
- 20 Dec 2014 New trial record